Oncolytic viruses are a novel group of therapeutic agents which enhance anti-tumour responses via a dual mechanism of action (MOA). The molecular and cellular MOA of oncolytic viruses are probably based on viral replication within transformed cells, interaction with tumour cell antiviral elements, induction of primary cell death, as well as start of innate and adaptive anti-tumour immunity. Nowadays, a great number of native and genetically modified viruses have been designed as oncolytic agents, and the first oncolytic virus (talimogene laherparepvec) has already been approved by the US Food and Drug Administration (FDA).
Taking advantage of our advanced OncoVirapy™ platform, Creative Biolabs provides customized, standardized, reliable and high-quality oncolytic virus for clients globally. Our oncolytic virus products are mainly developed based on the adenovirus, and the majority of them are armed oncolytic adenovirus. Armed oncolytic adenovirus can either be used as a separate therapeutic method in cancer therapy, or can be used with antibodies, car-t as a combination therapy. We also provide other types oncolytic virus for customer, you can contact us for more information and a detailed quote.
Fig 1. Life cycle of oncolytic adenoviruses and induction of autophagy in infected tumor cells. (Tazawa, H., 2017)
Adenovirus is a non-enveloped, linear, double-stranded DNA virus, and the genome of which is about 30–38 kb. Adenovirus consists of 52 distinct serotypes, which enables to be categorized into five subgroups (A to F) on account of their capacity to agglutinate red blood cells and their oncogenic potential in rodents. After binding to their primary receptors (e.g. CD46, Coxsackie-Adenovirus Receptor), the majority of human adenoviruses employ an RGD motif on the penton base protein. The protein docks the fiber to the capsid, to bind integrins for cell entry into endosomes. Following, viral DNA enters the nucleus via the pore and initiates transcription of early genes E1 which encode proteins controlled the cell cycle and the expression of the rest of early genes (E2 to E4). Hence, deleting the E1 protein domains which regulate the cell cycle or replacing the E1 promoter with tumor-selective promoters is generally used to construct oncolytic adenoviruses.
In order to enter and/or replicate selectively in cancer cells, oncolytic adenoviruses are genetically modified. Genetic modifications enable to solve the main obstacles found in virotherapy, such as the poor systemic tumor targeting. Besides, for efficient tumor targeting, the longer half life of adenovirus in blood gained after eliminating all capsid residues known to bind to soluble factors or cellular receptors will need to be combined with the capsid display of a tumor-specific ligand. Among numerous proteins displayed at the surface of the capsid, the fiber has been proven to be the best site to insert such a ligand.
Based on our well established OncoVirapy™ platform, we provide a full range of oncolytic adenovirus, such as oncolytic adenovirus expressing cytokine/chemokine, oncolytic adenovirus expressing antibody, as well as oncolytic adenovirus expressing immune checkpoint inhibitor. Apart from oncolytic adenovirus, Creative Biolabs also offer other types of oncolytic viruses, such as oncolytic vaccinia virus, oncolytic herpes simplex virus, oncolytic Newcastle disease virus, oncolytic Coxsackie virus, oncolytic reovirus. Our brilliant scientists are confident in providing high quality oncolytic virus to meet the needs for your research, preclinical study and drug development.
Please find the oncolytic virus products in following sections:
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved